Please login (Members) to view content or
(Nonmembers) this article.
0

No votes yet

Venlafaxine for the Control of Hot Flashes: Results of a Longitudinal Continuation Study

Debra Barton
Beth La Vasseur
Charles Loprinzi
Paul Novotny
Mary Beth Wilwerding
Jeff Sloan
ONF 2002, 29(1), 33-40 DOI: 10.1188/02.ONF.33-40

Purpose/Objectives: To evaluate the intermediate term efficacy and toxicity of the use of venlafaxine for the control of hot flashes.

Design: An open-label continuation phase study following a double-blind, randomized, placebo-controlled clinical trial that tested three doses of venlafaxine for the control of hot flashes.

Setting: North Central Cancer Treatment Group institutions.

Sample: 102 postmenopausal women.

Methods: Women could titrate venlafaxine to optimum efficacy while recording daily hot flash counts and weekly toxicity information.

Main Research Variables: Hot flash frequency, hot flash score.

Findings: The reduction in hot flashes previously reported in the randomized study phase was maintained during the open-label study. Toxicity did not appear to increase over time.

Conclusions: The data from this study provides evidence that venlafaxine has intermediate term efficacy and good tolerability as a treatment for hot flashes.

Implications for Nursing Practice: Nurses can inform symptomatic women that an effective nonhormonal alternative exists to control their hot flashes.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or